To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Xalatan Approved In Japan For Glaucoma And Ocular Hypertension URL: http://www.pslgroup.com/dg/EC42E.htm Doctor's Guide March 15, 1999
BRIDGEWATER, NJ -- March 15, 1999 -- Pharmacia & Upjohn's once-a-day glaucoma medication, Xalatan(TM) Sterile Ophthalmic Solution has been approved by Japan's Ministry of Health & Welfare for the treatment of glaucoma and ocular hypertension. Xalatan has been approved in more than 57 countries and is the leading prescribed glaucoma medication in several markets, including the United States. Xalatan is related to a class of compounds called prostaglandins that are present in various forms throughout the body. Prostaglandins act locally to increase drainage of aqueous humor, the fluid behind the eye's intraocular lens and reduce intraocular pressure. Lowering intraocular pressure through topical treatments is the standard of care in treating glaucoma. Related Links: Xalatan, Pharmacia & Upjohn --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.